CR8229A - Compuestos de 2-(quinoxalin-5- ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2 - Google Patents
Compuestos de 2-(quinoxalin-5- ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2Info
- Publication number
- CR8229A CR8229A CR8229A CR8229A CR8229A CR 8229 A CR8229 A CR 8229A CR 8229 A CR8229 A CR 8229A CR 8229 A CR8229 A CR 8229A CR 8229 A CR8229 A CR 8229A
- Authority
- CR
- Costa Rica
- Prior art keywords
- modulators
- compounds
- ilsulphonylamine
- colecistocinine
- quinoxalin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- ARLKVQYMFRECLV-JSGCOSHPSA-N (2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanamide Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(N)=O)=CNC2=C1 ARLKVQYMFRECLV-JSGCOSHPSA-N 0.000 abstract 2
- 108091005932 CCKBR Proteins 0.000 abstract 2
- SALREOBRLFDRED-UHFFFAOYSA-N 2-(sulfonylamino)quinoxaline Chemical class C1=CC=CC2=NC(N=S(=O)=O)=CN=C21 SALREOBRLFDRED-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ciertos compuestos de amidofenil-sulfonilamino-quinoxalina son moduladores de la CCK2 utiles en el tratamiento de las enfermedades mediadas por la CCK2
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49407403P | 2003-08-08 | 2003-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR8229A true CR8229A (es) | 2008-09-10 |
Family
ID=34193199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR8229A CR8229A (es) | 2003-08-08 | 2006-02-08 | Compuestos de 2-(quinoxalin-5- ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7304051B2 (es) |
| EP (2) | EP1651622B1 (es) |
| JP (2) | JP4818110B2 (es) |
| KR (1) | KR20060060007A (es) |
| CN (2) | CN1863781A (es) |
| AR (1) | AR045930A1 (es) |
| AT (2) | ATE403650T1 (es) |
| AU (2) | AU2004265312B2 (es) |
| BR (1) | BRPI0413449A (es) |
| CA (2) | CA2534887A1 (es) |
| CR (1) | CR8229A (es) |
| CY (1) | CY1106486T1 (es) |
| DE (2) | DE602004004663T2 (es) |
| DK (2) | DK1651622T3 (es) |
| EA (1) | EA200600203A1 (es) |
| EC (1) | ECSP066355A (es) |
| ES (2) | ES2281834T3 (es) |
| HR (1) | HRP20080559T3 (es) |
| IL (1) | IL173591A0 (es) |
| IS (1) | IS8280A (es) |
| LT (1) | LT5410B (es) |
| LV (1) | LV13453B (es) |
| MX (2) | MXPA06001482A (es) |
| NO (1) | NO20061122L (es) |
| NZ (1) | NZ545030A (es) |
| PL (2) | PL1651622T3 (es) |
| PT (2) | PT1651622E (es) |
| SG (1) | SG131114A1 (es) |
| SI (2) | SI1651621T1 (es) |
| TW (1) | TW200521120A (es) |
| UA (1) | UA84025C2 (es) |
| WO (2) | WO2005016896A1 (es) |
| ZA (1) | ZA200601946B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2281834T3 (es) * | 2003-08-08 | 2007-10-01 | Janssen Pharmaceutica N.V. | Metodo para producir compuestos de 2-(quinoxalina-5-il-sulfonilamino)-benzamida. |
| WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
| EP1763524A1 (en) * | 2004-04-23 | 2007-03-21 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| US7947833B2 (en) * | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| US7297816B2 (en) * | 2004-09-24 | 2007-11-20 | Janssen Pharmaceutica N.V. | Sulfonamide compounds |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US8592565B2 (en) * | 2007-01-12 | 2013-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation of azide-modified carbon surfaces for coupling to various species |
| EP2123644B1 (en) | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| WO2008124518A1 (en) * | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| EP2131244A3 (en) * | 2008-06-02 | 2012-04-11 | ASML Netherlands BV | Lithographic apparatus and method for measuring a pattern property |
| WO2009154754A2 (en) * | 2008-06-17 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| US20100305093A1 (en) * | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
| AU2010303270A1 (en) | 2009-10-09 | 2012-05-03 | Zafgen Corporation | Sulphone compounds for use in the treatment of obesity |
| ES2529233T3 (es) | 2010-07-09 | 2015-02-18 | Convergence Pharmaceuticals Limited | Compuestos tetrazol como bloqueadores de canales de calcio |
| EP2595988B1 (en) | 2010-07-22 | 2014-12-17 | Zafgen, Inc. | Tricyclic compounds and methds of making and using same |
| BR112013018771A2 (pt) | 2011-01-26 | 2019-09-17 | Zafgen Inc | compostos de tetrazol e métodos para fazer e usar os mesmos |
| WO2012154678A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic sulfonamide compounds and methods of making and using same |
| KR20140040739A (ko) | 2011-05-06 | 2014-04-03 | 자프겐 인크. | 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| AU2012253757B2 (en) | 2011-05-06 | 2017-04-13 | Zafgen Inc. | Partially saturated tricyclic compounds and methods of making and using same |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| EP2804856B1 (en) | 2012-01-18 | 2017-03-15 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| EP2804866B1 (en) | 2012-01-18 | 2016-11-16 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| HUE049728T2 (hu) * | 2012-03-01 | 2020-10-28 | Allergan Inc | Benzofurán-2-szulfonamid származékok, mint kemokin receptor modulátorok |
| SG11201503521QA (en) | 2012-11-05 | 2015-06-29 | Zafgen Inc | Methods of treating liver diseases |
| US9868717B2 (en) | 2012-11-05 | 2018-01-16 | Zafgen, Inc. | Tricyclic sulphonamide compounds and methods of making and using same |
| AU2013337282A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| JP6361168B2 (ja) * | 2013-06-17 | 2018-07-25 | Jsr株式会社 | 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物 |
| CN103524386B (zh) * | 2013-10-24 | 2016-05-18 | 江苏鼎龙科技有限公司 | 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法 |
| US10709714B2 (en) | 2013-11-22 | 2020-07-14 | Clifton Life Sciences LLC | Gastrin antagonists for treatment and prevention of osteoporosis |
| KR20170016754A (ko) * | 2015-08-04 | 2017-02-14 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN106565509A (zh) * | 2016-11-03 | 2017-04-19 | 江苏鼎龙科技有限公司 | 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法 |
| KR101894091B1 (ko) | 2018-01-23 | 2018-08-31 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN108218806B (zh) * | 2018-04-02 | 2019-03-01 | 上海馨远医药科技有限公司 | 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法 |
| CN111285806B (zh) * | 2018-12-06 | 2022-04-15 | 中国医学科学院药物研究所 | 吡唑类化合物及其制备方法、用途和药物组合物 |
| CN116675684B (zh) * | 2023-08-02 | 2023-11-07 | 上海翰森生物医药科技有限公司 | 含炔基稠环类衍生物拮抗剂、其制备方法和应用 |
| WO2025224201A1 (en) | 2024-04-26 | 2025-10-30 | F. Hoffmann-La Roche Ag | Novel process for the synthesis of substituted morpholines and thiomorpholines |
| CN118878477B (zh) * | 2024-05-31 | 2025-09-23 | 上海馨远医药科技有限公司 | 一种手性r或s的3-甲基吗啉的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200420D0 (en) * | 1992-01-09 | 1992-02-26 | James Black Foundation The Lim | Amino acid derivatives |
| ATE197146T1 (de) | 1993-08-10 | 2000-11-15 | Black James Foundation | Gastrin-und cck-rezeptorligande |
| DE69724644D1 (de) | 1996-12-10 | 2003-10-09 | Zeria Pharm Co Ltd | 1,5-benzodiazepinderivate |
| DE10121003A1 (de) | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121002A1 (de) | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10134721A1 (de) * | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
| ITTO20020674A1 (it) | 2002-07-26 | 2004-01-26 | Rotta Research Lab | Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico |
| US6943170B2 (en) * | 2002-11-14 | 2005-09-13 | Bristol-Myers Squibb Company | N-cycloalkylglycines as HIV protease inhibitors |
| ES2281834T3 (es) * | 2003-08-08 | 2007-10-01 | Janssen Pharmaceutica N.V. | Metodo para producir compuestos de 2-(quinoxalina-5-il-sulfonilamino)-benzamida. |
| US7297816B2 (en) * | 2004-09-24 | 2007-11-20 | Janssen Pharmaceutica N.V. | Sulfonamide compounds |
-
2004
- 2004-08-04 ES ES04780056T patent/ES2281834T3/es not_active Expired - Lifetime
- 2004-08-04 US US10/910,925 patent/US7304051B2/en not_active Expired - Lifetime
- 2004-08-04 CA CA002534887A patent/CA2534887A1/en not_active Abandoned
- 2004-08-04 PL PL04780056T patent/PL1651622T3/pl unknown
- 2004-08-04 AT AT04780055T patent/ATE403650T1/de not_active IP Right Cessation
- 2004-08-04 DE DE602004004663T patent/DE602004004663T2/de not_active Expired - Lifetime
- 2004-08-04 EP EP04780056A patent/EP1651622B1/en not_active Expired - Lifetime
- 2004-08-04 SI SI200430901T patent/SI1651621T1/sl unknown
- 2004-08-04 ES ES04780055T patent/ES2310294T3/es not_active Expired - Lifetime
- 2004-08-04 DE DE602004015614T patent/DE602004015614D1/de not_active Expired - Lifetime
- 2004-08-04 KR KR1020067002650A patent/KR20060060007A/ko not_active Withdrawn
- 2004-08-04 PT PT04780056T patent/PT1651622E/pt unknown
- 2004-08-04 PT PT04780055T patent/PT1651621E/pt unknown
- 2004-08-04 CN CNA2004800290901A patent/CN1863781A/zh active Pending
- 2004-08-04 US US10/910,983 patent/US7288651B2/en not_active Expired - Lifetime
- 2004-08-04 AU AU2004265312A patent/AU2004265312B2/en not_active Expired - Fee Related
- 2004-08-04 DK DK04780056T patent/DK1651622T3/da active
- 2004-08-04 EA EA200600203A patent/EA200600203A1/ru unknown
- 2004-08-04 WO PCT/US2004/025153 patent/WO2005016896A1/en not_active Ceased
- 2004-08-04 CA CA2534885A patent/CA2534885C/en not_active Expired - Lifetime
- 2004-08-04 BR BRPI0413449-4A patent/BRPI0413449A/pt not_active IP Right Cessation
- 2004-08-04 PL PL04780055T patent/PL1651621T3/pl unknown
- 2004-08-04 DK DK04780055T patent/DK1651621T3/da active
- 2004-08-04 AT AT04780056T patent/ATE353322T1/de not_active IP Right Cessation
- 2004-08-04 CN CNA200480029094XA patent/CN1863782A/zh active Pending
- 2004-08-04 WO PCT/US2004/025154 patent/WO2005016897A1/en not_active Ceased
- 2004-08-04 HR HR20080559T patent/HRP20080559T3/xx unknown
- 2004-08-04 UA UAA200601931A patent/UA84025C2/ru unknown
- 2004-08-04 SI SI200430245T patent/SI1651622T1/sl unknown
- 2004-08-04 AU AU2004265311A patent/AU2004265311A1/en not_active Abandoned
- 2004-08-04 MX MXPA06001482A patent/MXPA06001482A/es active IP Right Grant
- 2004-08-04 NZ NZ545030A patent/NZ545030A/en unknown
- 2004-08-04 SG SG200701706-4A patent/SG131114A1/en unknown
- 2004-08-04 JP JP2006523230A patent/JP4818110B2/ja not_active Expired - Fee Related
- 2004-08-04 MX MXPA06001550A patent/MXPA06001550A/es active IP Right Grant
- 2004-08-04 EP EP04780055A patent/EP1651621B1/en not_active Expired - Lifetime
- 2004-08-04 JP JP2006523231A patent/JP2007501842A/ja not_active Withdrawn
- 2004-08-06 AR ARP040102814A patent/AR045930A1/es not_active Application Discontinuation
- 2004-08-06 TW TW093123552A patent/TW200521120A/zh unknown
-
2006
- 2006-01-31 IS IS8280A patent/IS8280A/is unknown
- 2006-02-07 IL IL173591A patent/IL173591A0/en unknown
- 2006-02-08 CR CR8229A patent/CR8229A/es unknown
- 2006-02-08 EC EC2006006355A patent/ECSP066355A/es unknown
- 2006-02-08 LV LVP-06-18A patent/LV13453B/en unknown
- 2006-03-07 LT LT2006017A patent/LT5410B/lt not_active IP Right Cessation
- 2006-03-07 ZA ZA200601946A patent/ZA200601946B/en unknown
- 2006-03-08 NO NO20061122A patent/NO20061122L/no not_active Application Discontinuation
-
2007
- 2007-04-04 CY CY20071100473T patent/CY1106486T1/el unknown
- 2007-12-04 US US11/950,326 patent/US7563895B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8229A (es) | Compuestos de 2-(quinoxalin-5- ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2 | |
| SV2005001973A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) | |
| GT200100151A (es) | Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-dione como inhibidores de glucogeno sintasa quinasa-3b. | |
| NI200600094A (es) | Compuesto heterociclicos fusionados | |
| DE602004028359D1 (de) | Reinigung von biologisch produziertem 1,3-propandiol | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| CO5611065A2 (es) | Difluorometiltiazolilcarboxanilidas | |
| ECSP056064A (es) | Compuestos de benzopirano utiles para tratar estados inflamatorios | |
| UY28150A1 (es) | Agentes terapeuticos | |
| ATE267830T1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen | |
| MY142988A (en) | Novel aminobenzophenone compounds | |
| ECSP066549A (es) | Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos | |
| ECSP067120A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| PT1530509E (pt) | Esmeriladora e metodo para esmerilar uma peca a ser trabalhada | |
| ATE373645T1 (de) | Phenyltetrazol-verbindungen | |
| DE50310579D1 (de) | Furancarboxamide | |
| UY27451A1 (es) | 2,5-diamidoindoles sustituidos y su utilización | |
| ECSP044971A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson | |
| ECSP056057A (es) | Compuestos de benzo[1,2,5]tiadiazole | |
| DE60325194D1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
| DE50311756D1 (de) | Mikrobizide oxathiincarboxamide | |
| NO20053562L (no) | Nye aminobenzofenonforbindelser | |
| DE50303586D1 (de) | Methylthiophencarboxanilide | |
| DE60219495D1 (de) | Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten | |
| UY28439A1 (es) | "3-nitro-pirazolo(1,5-a)pirimidinas 7-sustituidas y composiciones y métodos relacionados" |